| Literature DB >> 33534075 |
Mushegh A Sahakyan1,2,3, Bård I Røsok4, Tore Tholfsen4, Dyre Kleive4, Anne Waage4, Dejan Ignjatovic5,6, Trond Buanes4,6, Knut Jørgen Labori4, Bjørn Edwin7,4,6.
Abstract
BACKGROUND: Distal pancreatectomy is the most common procedure in minimally-invasive pancreatic surgery. Data in the literature suggest that the learning curve flattens after performing up to 30 procedures. However, the exact number remains unclear.Entities:
Keywords: Adenocarcinoma; Conversion; Laparoscopy; Morbidity; Pancreatectomy
Mesh:
Year: 2021 PMID: 33534075 PMCID: PMC8741682 DOI: 10.1007/s00464-021-08306-3
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Experience with laparoscopic distal pancreatectomy at Oslo University Hospital, Rikshospitalet: 1997–2020
| Parameters | |
|---|---|
| Age, years, mean (SD) | 61 (14) |
| Body mass index, kg/m2, mean (SD) | 25.8 (4.6) |
| Gender, | |
| Female/male | 331 (51.7%)/309 (48.3%) |
| Cardiovascular diseases, | 110 (17.4%) |
| Chronic obstructive pulmonary disease, | 102 (15.9%) |
| Diabetes mellitus, | 102 (15.9%) |
| Total number of comorbidities, mean (SD) | 1.4 (1.3) |
| ASA score ≥ III, | 203 (32%) |
| Diagnosis of PDAC, | 138 (21.6%) |
| Tumor size, mm, median (range) | 34 (4–180) |
| Pioneer | 304 (47.5%) |
| Expert | 169 (26.4%) |
| Trainee 1 | 39 (6.1%) |
| Trainee 2 | 48 (7.5%) |
| Other | 80 (12.5%) |
| Spleen-preserving procedure, | 91 (14.2%) |
| Multivisceral resection, | 87 (13.6%) |
| Conversion, | 14 (2.2%) |
| Operative time, min, median (range) | 160 (30–560) |
| Estimated blood loss, ml, median (range) | 60 (10–6250) |
| Perioperative red blood cell transfusion, | 57 (9%) |
| 224 (35%) | |
| Severe complications (grade ≥ III), | 139 (21.7%) |
| 119 (18.6%) | |
| Grade B/C hemorrhage, | 33 (5.2%) |
| Reoperation, | 34 (5.3%) |
| Readmission, | 62 (9.7%) |
| 90-day mortality, | 4 (0.6%) |
| Postoperative length of stay, days, median (range) | 5 (2–81) |
ASA American Society of Anesthesiologists, PDAC pancreatic ductal adenocarcinoma
Description of cases that required conversion from laparoscopic to open distal pancreatectomy
| No | Patient BMI (kg/m2) | Diagnosis | Tumor size (mm) | Surgeon’s case no | Reason of conversion | Open procedure | Postoperative Complications |
|---|---|---|---|---|---|---|---|
| 1 | 25.2 | Chronic pancreatitis | – | 3 | Intraoperative bleeding | DP | – |
| 2 | 26.4 | Serosal cystadenoma | 60 | 43 | Bleeding from the upper pole of the spleen | DP; left adrenalectomy; stomach resection | – |
| 3 | 29.4 | NEN | 55 | 51 | Bleeding from the splenic vein | DP; left adrenalectomy; stomach resection | Thrombosis of the SMV |
| 4 | 25.8 | PDAC | 17 | 43 | Tumor adherence to the SMV | DP; resection of the SMV | – |
| 5 | 25.9 | PDAC | 88 | 44 | Tumor adherence to the portal vein | DP; resection of the portal vein; liver resection | – |
| 6 | 25.4 | Adenosquamous carcinoma | 85 | 54 | Bleeding from the portal vein | DP; resection of the portal vein | PF; hemorrhage |
| 7 | 24.4 | PDAC | 35 | 57 | Tumor infiltration into the duodenum and adherence to the middle colic artery | DP; resection of the duodenum | PF |
| 8 | 14.9 | PDAC | 55 | 59 | Bleeding from the splenic vein | DP | – |
| 9 | 35.2 | PDAC | 44 | 110 | Bleeding from the coeliac trunk | DP; repair of the vascular injury | Pulmonary embolism; PF |
| 10 | 26.2 | PDAC | 77 | 129 | Tumor adherence to the portovenous confluence | DP; resection of the portal vein | Urinary incontinence |
| 11 | 26.1 | Adenosquamous carcinoma | 70 | 24 | Tumor adherence to the portal vein | DP; resection of the portal vein | – |
| 12 | 38.9 | Serosal cystadenoma | 45 | 12 | Tumor adherence to the SMV | DP; resection of the SMV | Hemorrhage; thrombosis of the SMV; PF |
| 13 | 28.1 | PDAC | 9 | 19 | Fibrosis in the surgical area, suspicion of vascular affection | DP | PF |
| 14 | 33.2 | PDAC | 44 | 36 | Suspicion of vascular affection | DP | Pulmonary embolism |
DP distal pancreato-splenctomy, NEN neudoendocrine neoplasia, SMV superior mesenteric vein, PDAC pancreatic ductal adenocarcinoma, PF pancreatic fistula
Experiences of the pioneer and expert surgeons with LDP: first 40 cases of the pioneer (a); first and subsequent 40 cases of the pioneer (b); first 40 cases of the expert (c); first and subsequent 40 cases of the expert (d)
| Parameters | 1–10 | 11–20 | 21–30 | 31–40 | |
|---|---|---|---|---|---|
| (a) | |||||
| Age, years, mean (SD) | 56.7 (12.2) | 56 (15.2) | 62.3 (10) | 59.8 (12.9) | 0.41 |
| BMI, kg/m2, mean (SD)a | 30.6 (7.7) | 24.6 (1.9) | 23.6 (3.2) | 24.6 (3.3) | |
| PUAS, | 4 | 6 | 6 | 3 | 0.54 |
| Diagnosis (PDAC), | 1 | 2 | 2 | 2 | 1.0 |
| Tumor size, mm, median (range)b | 23.5 (4–70) | 25 (11–75) | 19.5 (15–23) | 44.5 (29–70) | |
| Spleen-preserving procedure, | 1 | 2 | 4 | 1 | 0.46 |
| Multivisceral resection, | 0 | 2 | 2 | 1 | 0.73 |
| Blood loss, ml, median (range) | 100 (30–1000) | 300 (30–1500) | 80 (30–350) | 250 (30–3000) | 0.5 |
| Operative time, min, median (range) | 248 (125–360) | 233 (180–520) | 215 (123–300) | 188 (135–260) | 0.16 |
| Intraoperative adverse events, | 2 | 3 | 0 | 2 | 0.46 |
| Conversion, | 1 | 0 | 0 | 0 | 1.0 |
| Postoperative complications, | 3 | 6 | 4 | 4 | 0.68 |
| Severe complications, | 3 | 3 | 2 | 2 | 1.0 |
| CR-PF, | 2 | 2 | 0 | 1 | 0.73 |
| Grade B/C hemorrhage, | 1 | 1 | 0 | 1 | 1.0 |
| Reoperation, | 0 | 0 | 0 | 1 | 1.0 |
| Mortality, | 0 | 0 | 0 | 0 | – |
| Hospital stay, days, median (range) | 6 (4–8) | 6 (2–12) | 6 (2–11) | 5 (3–16) | 0.73 |
BMI body mass index, PUAS previous upper abdominal surgery, PDAC pancreatic ductal adenocarcinoma, CR-PF clinically relevant pancreatic fistula
aSignificant difference between the periods 1 and 2–4
bSignificant difference between the periods 1–3 and 4
The initial experience of the trainees with laparoscopic distal pancreatectomy: trainee 1 (a) and trainee 2 (b)
| Parameters | 1–10 | 11–20 | 21–30 | 31–39 | |
|---|---|---|---|---|---|
| (a) | |||||
| Age, years, mean (SD) | 62.8 (12.3) | 61.7 (13.7) | 59 (15.5) | 57.4 (14.3) | 0.83 |
| BMI, kg/m2, mean (SD) | 25.2 (3) | 28.7 (6.1) | 27.4 (5.3) | 28.3 (6) | 0.45 |
| PUAS, | 3 | 5 | 4 | 5 | 0.77 |
| Diagnosis (PDAC), | 0 | 1 | 1 | 2 | 0.43 |
| Tumor size, mm, median (range) | 47 (11–114) | 47.5 (20–95) | 35 (16–60) | 50 (27–80) | 0.37 |
| Pioneer/expert surgeon assistance/supervision, | 5 | 6 | 3 | 0 | |
| Spleen-preserving procedure, | 0 | 1 | 0 | 0 | 1.0 |
| Multivisceral resection, | 0 | 1 | 1 | 1 | 0.89 |
| Blood loss, ml, median (range) | 50 (30–300) | 125 (50–3700) | 50 (20–250) | 100 (10–400) | 0.27 |
| Operative time, min, median (range) | 149 (100–202) | 162 (125–341) | 159 (78–314) | 188 (122–219) | 0.36 |
| Intraoperative adverse events, | 0 | 3 | 0 | 2 | 0.08 |
| Conversion, | 0 | 1 | 0 | 0 | 1.0 |
| Postoperative complications, | 5 | 3 | 3 | 1 | 0.4 |
| Severe complications, | 4 | 2 | 2 | 1 | 0.56 |
| CR-PF, | 2 | 2 | 2 | 1 | 1.0 |
| Grade B/C hemorrhage, | 1 | 1 | 1 | 0 | 1.0 |
| Reoperation, | 0 | 1 | 1 | 0 | 1.0 |
| Mortality, | 0 | 0 | 0 | 0 | – |
| Hospital stay, days, median (range) | 7 (4–19) | 4 (3–38) | 6 (3–13) | 4 (3–7) | 0.08 |
BMI body mass index, PUAS previous upper abdominal surgery, PDAC pancreatic ductal adenocarcinoma, CR-PF clinically relevant pancreatic fistula
Experiences with the first 30 laparoscopic distal pancreatectomies for the pioneer and the adopters without senior surgeon assistance
| Parameters | Pioneer | Expert | Trainee 1 | Trainee 2 | |
|---|---|---|---|---|---|
| Within individual LDP series | 1–30 | 1–46 | 1–39 | 1–48 | |
| Age, years, mean (SD) | 58.6 (13.7) | 63.6 (10.7) | 60.1 (13.3) | 63.4 (12.1) | 0.33 |
| BMI, kg/m2, mean (SD) | 25.9 (5.4) | 24.8 (3.3) | 27.4 (4.8) | 26.5 (3.9) | 0.13 |
| ASA ≥ III, | 10 (33.3%) | 11 (36.7%) | 10 (33.3%) | 13 (43.3%) | 0.72 |
| PUAS, | 16 (53.3%) | 14 (46.7%) | 14 (46.7%) | 15 (50%) | 0.95 |
| Diagnosis (PDAC), | 5 (16.7%) | 7 (23.3%) | 3 (10%) | 8 (26.7%) | 0.37 |
| Tumor size, mm, median (range) | 25 (4–80) | 25 (7–88) | 37 (13–80) | 31 (11–110) | 0.15 |
| Spleen-preserving procedure, | 7 (23.3%) | 11 (36.7%) | 1 (3.3%) | 1 (3.3%) | |
| Multivisceral resection, | 4 (13.3%) | 6 (20%) | 1 (3.3%) | 0 (0%) | |
| Blood loss, ml, median (range) | 120 (30–1500) | 50 (30–900) | 80 (10–400) | 50 (20–750) | 0.2 |
| Operative time, min, median (range) | 230 (123–520) | 188 (110–356) | 161 (78–314) | 156 (71–341) | |
| Intraoperative adverse events, | 5 (16.7%) | 3 (10%) | 3 (10%) | 3 (10%) | 0.89 |
| Conversion, | 1 (3.3%) | 2 (6.7%) | 0 (0%) | 1 (3.3%) | 0.9 |
| Postoperative complications, | 13 (43.3%) | 11 (36.7%) | 8 (26.7%) | 9 (30%) | 0.54 |
| Severe complications, | 8 (26.7%) | 7 (23.3%) | 7 (23.3%) | 5 (16.7%) | 0.87 |
| CR-PF, | 4 (13.3%) | 5 (16.7%) | 4 (13.3%) | 4 (13.3%) | 1.0 |
| Grade B/C hemorrhage, | 2 (6.7%) | 3 (10%) | 2 (6.7%) | 1 (3.3%) | 0.96 |
| Reoperation, | 0 (0%) | 2 (6.7%) | 1 (3.3%) | 1 (3.3%) | 0.9 |
| Mortality, | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | – |
| Readmission, | 3 (10%) | 3 (10%) | 4 (13.3%) | 4 (13.3%) | 1.0 |
| Hospital stay, days, median (range) | 6 (2–12) | 6 (2–35) | 5 (3–19) | 4 (2–40) |
BMI body mass index, PUAS previous upper abdominal surgery, PDAC pancreatic ductal adenocarcinoma, CR-PF clinically relevant pancreatic fistula
┼Significant difference between the pioneer/expert and trainees
╪Significant difference between the expert and trainees
*Significant difference between the pioneer and others
¶Significant difference between the pioneer/expert and trainee 2